Bio-Thera Solutions
Quick facts
Marketed products
- QLETLI · Other
Phase 3 pipeline
- Actemra(EU-licensed) · Immunology
Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses. - BAT1406 · Oncology
BAT1406 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. - BAT1706 · Oncology
BAT1706 is a bispecific antibody that simultaneously engages PD-1 on T cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. - BAT1806 · Oncology
BAT1806 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. - BAT2206 · Oncology
BAT2206 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses. - BAT2306 · Oncology
BAT2306 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. - BAT2506 injection · Oncology
BAT2506 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. - BAT3306 · Oncology
BAT3306 is a monoclonal antibody targeting PD-1. - BAT5906 injection · Oncology
BAT5906 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. - BAT8001 for injection · Oncology
BAT8001 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity. - EU Avastin® · Oncology
Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth. - EU Simponi · Immunology
Simponi is a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation in autoimmune diseases. - Paclitaxel for Injection · Oncology
Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. - Stelara (EU-sourced) · Immunology / Gastroenterology / Dermatology
Stelara is a human monoclonal antibody that blocks the IL-12 and IL-23 cytokines to suppress immune-mediated inflammation. - US-Keytruda® · Oncology
US-Keytruda is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
Phase 2 pipeline
- BAT4406F Injection · Oncology
BAT4406F Injection is a monoclonal antibody targeting CD47.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Bio-Thera Solutions
What are Bio-Thera Solutions's marketed drugs?
Top marketed products include QLETLI.
What is Bio-Thera Solutions's pipeline?
Bio-Thera Solutions has 15 drugs in Phase 3, 1 in Phase 2, 4 in Phase 1. Late-stage candidates include Actemra(EU-licensed), BAT1406, BAT1706, BAT1806.
Related
- QLETLI · Other
- Sector hub: All tracked pharma companies